Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields “
Post# of 421
(Total Views: 79)
Posted On: 09/05/2024 5:04:55 PM
Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields “Extremely Interesting” Results for DehydraTECH(TM) Liraglutide in Ongoing Diabetes Animal Study
- Lexaria, a global innovator in drug delivery platforms, has just announced its 4-week and 8-week blood glucose results from its WEIGHT-A24-1 animal study
- Two formulations from the study posted outstanding performance, with each utilizing the company’s patented DehydraTECH(TM) technology
- DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A &
posted blood sugar level reductions of 2.50%, 1.90%, and 1.53%, respectively
- These results build on the positive results from Lexaria’s 2023 DIAB-A22-1 animal study, which showed a 16.7% blood sugar concentration increase relative to baseline by day 56 for the obese control group that got no treatment
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its 4-week and 8-week blood glucose results from its WEIGHT-A24-1 animal study (the “study”). This study will examine diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and DehydraTECH-processed cannabidiol, alone and in combination . The ongoing study uses diabetic, pre-conditioned Zucker rats, falling in one of three study arms, with dosing lasting 12 weeks (https://nnw.fm/KLggI ).
Two formulations posted outstanding performance from the study as of day 56 – DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A & . Most notably, they each posted blood sugar level reductions of 2.50%, 1.90%, and 1.53% respectively. DehydraTECH-liraglutide specifically saw a -2.08% change as of day 28 and a -2.50% change as of day 56 in what Lexaria’s management described as “extremely interesting.”
For Lexaria, these results build on the positive results from its 2023 DIAB-A22-1 animal study, which showed a 16.7% blood sugar concentration increase relative to baseline by day 56 for the obese control group that received no treatment. For the current study, each of the eight active groups of animals either experienced a smaller increase or an actual decrease in blood sugar level relative to baseline compared to the obese control group in the previous study.
The ongoing study featured eight groups. Groups A through D were administered with different DehydraTECH-CBD compositions. Groups E and F utilized reformulated Rybelsus DehydraTECH compositions, whereas groups G and G used pure glucagon-like peptide-1 (“GLP-1”) drugs semaglutide and liraglutide respectively in DehydraTECH compositions. Additional results from this study are expected soon. However, Lexaria’s management remains optimistic that it will replicate both the interim and previous results, ultimately demonstrating the superiority of its DehydraTECH technology.
The global diabetes treatment market was valued at $79.25 billion in 2023. It is projected that by 2032, it will have surpassed $153 billion in valuation, mainly influenced by the growing prevalence of the condition and the increasing demand for effective drug therapies (https://nnw.fm/O4eHH ). For the longest time, treatment options have involved painful injections, which, to many, have been a source of discomfort and, to some, an outright deterrent. Lexaria looks to carve out a piece of the diabetes treatment market share by offering an oral alternative and is banking on its DehydraTECH technology to achieve that. Its previous and ongoing studies are a testament to its commitment to this goal and its pledge to creating shareholder value.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- Lexaria, a global innovator in drug delivery platforms, has just announced its 4-week and 8-week blood glucose results from its WEIGHT-A24-1 animal study
- Two formulations from the study posted outstanding performance, with each utilizing the company’s patented DehydraTECH(TM) technology
- DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A &
posted blood sugar level reductions of 2.50%, 1.90%, and 1.53%, respectively - These results build on the positive results from Lexaria’s 2023 DIAB-A22-1 animal study, which showed a 16.7% blood sugar concentration increase relative to baseline by day 56 for the obese control group that got no treatment
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its 4-week and 8-week blood glucose results from its WEIGHT-A24-1 animal study (the “study”). This study will examine diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and DehydraTECH-processed cannabidiol, alone and in combination . The ongoing study uses diabetic, pre-conditioned Zucker rats, falling in one of three study arms, with dosing lasting 12 weeks (https://nnw.fm/KLggI ).
Two formulations posted outstanding performance from the study as of day 56 – DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A &
. Most notably, they each posted blood sugar level reductions of 2.50%, 1.90%, and 1.53% respectively. DehydraTECH-liraglutide specifically saw a -2.08% change as of day 28 and a -2.50% change as of day 56 in what Lexaria’s management described as “extremely interesting.” For Lexaria, these results build on the positive results from its 2023 DIAB-A22-1 animal study, which showed a 16.7% blood sugar concentration increase relative to baseline by day 56 for the obese control group that received no treatment. For the current study, each of the eight active groups of animals either experienced a smaller increase or an actual decrease in blood sugar level relative to baseline compared to the obese control group in the previous study.
The ongoing study featured eight groups. Groups A through D were administered with different DehydraTECH-CBD compositions. Groups E and F utilized reformulated Rybelsus DehydraTECH compositions, whereas groups G and G used pure glucagon-like peptide-1 (“GLP-1”) drugs semaglutide and liraglutide respectively in DehydraTECH compositions. Additional results from this study are expected soon. However, Lexaria’s management remains optimistic that it will replicate both the interim and previous results, ultimately demonstrating the superiority of its DehydraTECH technology.
The global diabetes treatment market was valued at $79.25 billion in 2023. It is projected that by 2032, it will have surpassed $153 billion in valuation, mainly influenced by the growing prevalence of the condition and the increasing demand for effective drug therapies (https://nnw.fm/O4eHH ). For the longest time, treatment options have involved painful injections, which, to many, have been a source of discomfort and, to some, an outright deterrent. Lexaria looks to carve out a piece of the diabetes treatment market share by offering an oral alternative and is banking on its DehydraTECH technology to achieve that. Its previous and ongoing studies are a testament to its commitment to this goal and its pledge to creating shareholder value.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)